Developer docs
API playgroundTry for free, no card

Search company profiles

Gilgamesh Pharmaceuticals

Full company profile

uuid00004r9

Namestring
Gilgamesh Pharmaceuticals
Legal namestring
Gilgamesh Pharma Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company founded in 2019 and headquartered in New York that develops psychedelic-inspired therapeutics and neuroplastogens for major depressive disorder and related neuropsychiatric conditions. The company's core technology spans three differentiated chemical approaches: NMDA receptor antagonism (blixeprodil/GM-1020), ibogaine analog medicinal chemistry designed to retain therapeutic activity while eliminating cardiotoxicity (GM-3009), and next-generation psychedelic compounds (bretisilocin/GM-2505). Blixeprodil produced positive Phase 2a results demonstrating a 6.3-point greater reduction in MADRS versus placebo at 24 hours (p=0.006, effect size 0.85) with a 53% remission rate over two weeks of twice-weekly dosing and durable effects through 28 days, supporting advancement into late-stage studies in 2026. GM-3009 is positioned to enter Phase 1 studies in 2026, while bretisilocin was divested to AbbVie in October 2025 for up to $1.2 billion.

Gilgamesh operates as a pre-revenue R&D organization with 11-50 employees, generating no disclosed commercial product revenue. Capital formation has occurred primarily through venture financing and a NIDA grant, with cumulative disclosed funding exceeding $140 million across seed (2020), Series A (2021, $27M), Series B (2022, $39M led by Prime Movers Lab), a $14M NIDA grant (2024), and a post-AbbVie Series A (March 2026, $60M led by Satori Neuro). The AbbVie transaction for bretisilocin represents both the company's primary liquidity event to date and a strategic validation of plasticity-driven mechanisms for MDD. Leadership is founder-led under CEO Jonathan Sporn, with scientific co-founders Andrew Kruegel (Discovery Chemist), Dalibor Sames, Jeffrey Witkin (Preclinical Pharmacologist), and Mike Cunningham providing the medicinal chemistry expertise underlying the platform.

The go-to-market path for the remaining pipeline (blixeprodil and GM-3009) is not yet defined but will likely follow the established biotech playbook of advancing through Phase 2/3 development toward either partnership with a larger pharmaceutical company for commercialization or direct commercialization in core indications. Patient end markets are individuals suffering from moderate-to-severe major depressive disorder, including treatment-resistant depression, and broader neuropsychiatric populations. Pricing models and reimbursement strategies are not publicly disclosed, consistent with the company's clinical-stage status and absence of approved products.

Short descriptiontext

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic-inspired therapeutics and neuroplastogens, including NMDA receptor antagonists and cardio-safe ibogaine analogs, for patients with major depressive disorder and other neuropsychiatric conditions.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic therapeutics, NMDA receptor antagonists, neuroplastogen drug development, clinical-stage biopharmaceuticals, neuropsychiatric drug discovery
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuropsychiatric Therapeutics
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Gilgamesh Pharmaceuticals is a clinical-stage neuroscience company that discovers and develops novel small-molecule therapeutics for major depressive disorder and other neuropsychiatric conditions. Its pipeline comprises proprietary drug candidates including oral NMDA receptor antagonists, cardio-safe ibogaine analogs, and next-generation psychedelic-inspired neuroplastogens. The company monetizes its pipeline primarily through out-licensing and asset-sale transactions with larger pharmaceutical partners, exemplified by the up-to-$1.2 billion AbbVie acquisition of bretisilocin (GM-2505).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 2 trials showed 6.3-point greater reduction in MADRS vs. placebo at 24 hours (p=0.006, effect size=0.85) with 53% remission rate after twice-weekly dosing over 2 weeks and durable effects through 28 days of follow-up
Product overview1 text field

Gilgamesh Pharmaceuticals is a clinical-stage neuroscience company developing a portfolio of neuropsychiatric therapeutics, including novel drug candidates for major depressive disorder and other psychiatric conditions. The core pipeline includes blixeprodil (GM-1020), an oral NMDA receptor antagonist which achieved positive Phase 2a results and is advancing to late-stage studies, and GM-3009, a cardio-safe ibogaine analog expected to enter Phase 1 studies. The company also developed bretisilocin (GM-2505), which was acquired by AbbVie for up to $1.2 billion. The company operates with Series A financing of $60 million secured in March 2026.

Product and service3 records
1Blixeprodil (GM-1020)
CategoryCore neuropsychiatric therapeutic candidate
Description

Oral NMDA receptor antagonist being developed as a treatment for major depressive disorder (MDD); demonstrated clinically meaningful and statistically significant improvements in Phase 2 trials and is advancing to late-stage clinical studies. Targeted at patients with moderate-to-severe MDD, including treatment-resistant depression.

2GM-3009 (Cardio-safe ibogaine analog)
CategoryCore neuropsychiatric therapeutic candidate
Description

Cardio-safe ibogaine analog being developed for neuropsychiatric disorders; designed to mitigate the cardiotoxicity that has historically limited ibogaine-based drug development. Expected to enter Phase 1 studies in 2026.

3Bretisilocin (GM-2505)
CategoryOut-licensed neuropsychiatric therapeutic candidate
Description

Next-generation psychedelic compound that was in Phase 2 development for major depressive disorder; the asset was acquired by AbbVie in October 2025 for up to $1.2 billion.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS biopharma developing rapid-acting and novel mechanisms for depression (e.g., Zurzuvae for postpartum depression). Directly comparable as a CNS-focused innovator with MDD as a lead indication and overlapping neuroplastogen-style science.

TypeDirect peer
Description

Commercial-stage CNS company with FDA-approved MDD therapies (Auvelity). Comparable target indication (MDD), oral small-molecule development approach, and similar commercial ambition in depression.

TypeDirect peer
Description

Clinical-stage developer of psilocybin-based therapies for treatment-resistant depression. Closely comparable in psychedelic-inspired neuropsychiatric drug development and MDD focus, although with a hallucinogenic rather than non-hallucinogenic profile.

4atai Life Sciences
TypeDirect peer
Description

Clinical-stage biotech developing psychedelic and mental-health therapeutics including NMDA antagonists and neuroplastogens. Highly comparable pipeline strategy, target indications (MDD, treatment-resistant depression), and platform approach.

5MindMed
TypeDirect peer
Description

Clinical-stage developer of psychedelic-inspired medicines (including an LSD program for MDD and an MDMA-inspired candidate). Comparable psychedelic/neuroplastogen approach to CNS disorders and similar stage of development.

TypeDirect peer
Description

Clinical-stage neuroscience company targeting brain diseases including MDD. Comparable CNS focus, well-capitalized private-stage structure, and broad neuropsychiatric pipeline philosophy.

7Johnson & Johnson (Janssen)
TypeBroad incumbent
Description

Large pharma that commercialized Spravato (esketamine) for treatment-resistant depression. Sets the incumbent benchmark in rapid-acting MDD therapeutics and represents the most significant direct commercial competitor to Gilgamesh's blixeprodil.

TypeBroad incumbent
Description

Global pharmaceutical company that acquired Gilgamesh's bretisilocin asset for up to $1.2B in October 2025 and is parent through Warka Intermediate LLC. Direct counterparty in the most material commercial validation event in Gilgamesh's history.

TypeEmerging player
Description

Clinical-stage developer of psychedelic-based therapeutics for mental health. Comparable in psychedelic drug development, but with greater emphasis on deuterated psilocybin analogs and depression indications.

10Boehringer Ingelheim (CNS pipeline)
TypeBroad incumbent
Description

Major pharmaceutical company with active CNS and mental-health pipeline initiatives, including partnerships in psychedelic-inspired mechanisms. Relevant broader incumbent shaping the M&A and partnering landscape for CNS innovators.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gilgamesh Pharmaceuticals

Neuropsychiatric Therapeuticsgilgameshpharmaceutical.com

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic-inspired therapeutics and neuroplastogens, including NMDA receptor antagonists and cardio-safe ibogaine analogs, for patients with major depressive disorder and other neuropsychiatric conditions.

What Gilgamesh Pharmaceuticals does

Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company founded in 2019 and headquartered in New York that develops psychedelic-inspired therapeutics and neuroplastogens for major depressive disorder and related neuropsychiatric conditions. The company's core technology spans three differentiated chemical approaches: NMDA receptor antagonism (blixeprodil/GM-1020), ibogaine analog medicinal chemistry designed to retain therapeutic activity while eliminating cardiotoxicity (GM-3009), and next-generation psychedelic compounds (bretisilocin/GM-2505). Blixeprodil produced positive Phase 2a results demonstrating a 6.3-point greater reduction in MADRS versus placebo at 24 hours (p=0.006, effect size 0.85) with a 53% remission rate over two weeks of twice-weekly dosing and durable effects through 28 days, supporting advancement into late-stage studies in 2026. GM-3009 is positioned to enter Phase 1 studies in 2026, while bretisilocin was divested to AbbVie in October 2025 for up to $1.2 billion.

Gilgamesh operates as a pre-revenue R&D organization with 11-50 employees, generating no disclosed commercial product revenue. Capital formation has occurred primarily through venture financing and a NIDA grant, with cumulative disclosed funding exceeding $140 million across seed (2020), Series A (2021, $27M), Series B (2022, $39M led by Prime Movers Lab), a $14M NIDA grant (2024), and a post-AbbVie Series A (March 2026, $60M led by Satori Neuro). The AbbVie transaction for bretisilocin represents both the company's primary liquidity event to date and a strategic validation of plasticity-driven mechanisms for MDD. Leadership is founder-led under CEO Jonathan Sporn, with scientific co-founders Andrew Kruegel (Discovery Chemist), Dalibor Sames, Jeffrey Witkin (Preclinical Pharmacologist), and Mike Cunningham providing the medicinal chemistry expertise underlying the platform.

The go-to-market path for the remaining pipeline (blixeprodil and GM-3009) is not yet defined but will likely follow the established biotech playbook of advancing through Phase 2/3 development toward either partnership with a larger pharmaceutical company for commercialization or direct commercialization in core indications. Patient end markets are individuals suffering from moderate-to-severe major depressive disorder, including treatment-resistant depression, and broader neuropsychiatric populations. Pricing models and reimbursement strategies are not publicly disclosed, consistent with the company's clinical-stage status and absence of approved products.

Gilgamesh Pharmaceuticals firmographics

Firmographics
Name
Gilgamesh Pharmaceuticals
Legal name
Gilgamesh Pharma Inc.
Website
https://gilgameshpharmaceutical.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
1–10 employees
Short description
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic-inspired therapeutics and neuroplastogens, including NMDA receptor antagonists and cardio-safe ibogaine analogs, for patients with major depressive disorder and other neuropsychiatric conditions.
Ownership category
akta.pro rank

Gilgamesh Pharmaceuticals industry classification

Industry
Product category
Neuropsychiatric Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Psychedelic therapeutics
  • NMDA receptor antagonists
  • Neuroplastogen drug development
  • Clinical-stage biopharmaceuticals
  • Neuropsychiatric drug discovery

Where Gilgamesh Pharmaceuticals is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Gilgamesh Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Gilgamesh Pharmaceuticals product offering

Product offering

Core offering

Gilgamesh Pharmaceuticals is a clinical-stage neuroscience company that discovers and develops novel small-molecule therapeutics for major depressive disorder and other neuropsychiatric conditions. Its pipeline comprises proprietary drug candidates including oral NMDA receptor antagonists, cardio-safe ibogaine analogs, and next-generation psychedelic-inspired neuroplastogens. The company monetizes its pipeline primarily through out-licensing and asset-sale transactions with larger pharmaceutical partners, exemplified by the up-to-$1.2 billion AbbVie acquisition of bretisilocin (GM-2505).

Product overview

Gilgamesh Pharmaceuticals is a clinical-stage neuroscience company developing a portfolio of neuropsychiatric therapeutics, including novel drug candidates for major depressive disorder and other psychiatric conditions. The core pipeline includes blixeprodil (GM-1020), an oral NMDA receptor antagonist which achieved positive Phase 2a results and is advancing to late-stage studies, and GM-3009, a cardio-safe ibogaine analog expected to enter Phase 1 studies. The company also developed bretisilocin (GM-2505), which was acquired by AbbVie for up to $1.2 billion. The company operates with Series A financing of $60 million secured in March 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • Blixeprodil (GM-1020) Oral NMDA receptor antagonist being developed as a treatment for major depressive disorder (MDD); demonstrated clinically meaningful and statistically significant improvements in Phase 2 trials and is advancing to late-stage clinical studies. Targeted at patients with moderate-to-severe MDD, including treatment-resistant depression.
  • GM-3009 (Cardio-safe ibogaine analog) Cardio-safe ibogaine analog being developed for neuropsychiatric disorders; designed to mitigate the cardiotoxicity that has historically limited ibogaine-based drug development. Expected to enter Phase 1 studies in 2026.
  • Bretisilocin (GM-2505) Next-generation psychedelic compound that was in Phase 2 development for major depressive disorder; the asset was acquired by AbbVie in October 2025 for up to $1.2 billion.

Quantifiable outcome

  • Phase 2 trials showed 6.3-point greater reduction in MADRS vs. placebo at 24 hours (p=0.006, effect size=0.85) with 53% remission rate after twice-weekly dosing over 2 weeks and durable effects through 28 days of follow-up

Companies that use Gilgamesh Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles1 record

Gilgamesh Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Gilgamesh Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Gilgamesh Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: Clinical-stage CNS biopharma developing rapid-acting and novel mechanisms for depression (e.g., Zurzuvae for postpartum depression). Directly comparable as a CNS-focused innovator with MDD as a lead indication and overlapping neuroplastogen-style science.
  • Axsome Therapeutics: Commercial-stage CNS company with FDA-approved MDD therapies (Auvelity). Comparable target indication (MDD), oral small-molecule development approach, and similar commercial ambition in depression.
  • Compass Pathways: Clinical-stage developer of psilocybin-based therapies for treatment-resistant depression. Closely comparable in psychedelic-inspired neuropsychiatric drug development and MDD focus, although with a hallucinogenic rather than non-hallucinogenic profile.
  • atai Life Sciences: Clinical-stage biotech developing psychedelic and mental-health therapeutics including NMDA antagonists and neuroplastogens. Highly comparable pipeline strategy, target indications (MDD, treatment-resistant depression), and platform approach.
  • MindMed: Clinical-stage developer of psychedelic-inspired medicines (including an LSD program for MDD and an MDMA-inspired candidate). Comparable psychedelic/neuroplastogen approach to CNS disorders and similar stage of development.
  • Neumora Therapeutics: Clinical-stage neuroscience company targeting brain diseases including MDD. Comparable CNS focus, well-capitalized private-stage structure, and broad neuropsychiatric pipeline philosophy.

Broad incumbents

  • Johnson & Johnson (Janssen): Large pharma that commercialized Spravato (esketamine) for treatment-resistant depression. Sets the incumbent benchmark in rapid-acting MDD therapeutics and represents the most significant direct commercial competitor to Gilgamesh's blixeprodil.
  • AbbVie: Global pharmaceutical company that acquired Gilgamesh's bretisilocin asset for up to $1.2B in October 2025 and is parent through Warka Intermediate LLC. Direct counterparty in the most material commercial validation event in Gilgamesh's history.
  • Boehringer Ingelheim (CNS pipeline): Major pharmaceutical company with active CNS and mental-health pipeline initiatives, including partnerships in psychedelic-inspired mechanisms. Relevant broader incumbent shaping the M&A and partnering landscape for CNS innovators.

Emerging players

  • Cybin: Clinical-stage developer of psychedelic-based therapeutics for mental health. Comparable in psychedelic drug development, but with greater emphasis on deuterated psilocybin analogs and depression indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Gilgamesh Pharmaceuticals social profiles

Digital presence

Gilgamesh Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gilgamesh Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Gilgamesh Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gilgamesh Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gilgamesh Pharmaceuticals

What does Gilgamesh Pharmaceuticals do?

Gilgamesh Pharmaceuticals is a clinical-stage neuroscience company that discovers and develops novel small-molecule therapeutics for major depressive disorder and other neuropsychiatric conditions. Its pipeline comprises proprietary drug candidates including oral NMDA receptor antagonists, cardio-safe ibogaine analogs, and next-generation psychedelic-inspired neuroplastogens. The company monetizes its pipeline primarily through out-licensing and asset-sale transactions with larger pharmaceutical partners, exemplified by the up-to-$1.2 billion AbbVie acquisition of bretisilocin (GM-2505).

Is Gilgamesh Pharmaceuticals a public or private company?

Gilgamesh Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Gilgamesh Pharmaceuticals founded?

Gilgamesh Pharmaceuticals was founded in 2019. It employs 1 to 10 people.

Where is Gilgamesh Pharmaceuticals based?

Gilgamesh Pharmaceuticals is headquartered in New York, United States, in the North America region.

Who are Gilgamesh Pharmaceuticals's main competitors?

Direct peers on record are Sage Therapeutics, Axsome Therapeutics, Compass Pathways, atai Life Sciences, MindMed and Neumora Therapeutics. Broad incumbents are Johnson & Johnson (Janssen), AbbVie and Boehringer Ingelheim (CNS pipeline). Cybin is listed as an emerging player.

Does Gilgamesh Pharmaceuticals have an API?

No public API is recorded for Gilgamesh Pharmaceuticals.

What industry is Gilgamesh Pharmaceuticals in?

Gilgamesh Pharmaceuticals's product category is Neuropsychiatric Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AmbitoDe una oficina de 3 metros a un acuerdo multimillonario: la historia de la startup que conquistó Big PharmaAbbVie agreed to pay $1.2 billion for Gilgamesh Pharma's buprenorphine, a lab-created substance for depression treatment. The deal followed a 94% remission rate in a small European trial, with further testing planned for late 2026 to early 2027. Gilgamesh will continue developing new drugs, including blixeprodil and ibogaína-based treatments.BioSpaceDespite FDA trial clearance, ibogaine metabolite won’t receive red carpet treatmentDemeRx's noribogaine, an active metabolite of the psychedelic compound ibogaine, received FDA clearance in late April for first-in-human testing in the U.S., with plans to launch a Phase 2 trial in alcohol use disorder early next year, backed by a planned $25 million Series B financing. The approval follows President Trump's executive order to accelerate psychedelic therapies and Joe Rogan's advocacy, though ibogaine carries documented cardiotoxicity risks linked to 33 recorded deaths as of 2022, historically deterring pharmaceutical investment. Other companies in the space include Beond, which operates ibogaine treatment clinics in Mexico, and Gilgamesh Pharmaceuticals, which is developing a cardiac-safe ibogaine analog called GM-3009 under a deal with AbbVie.BioSpaceHow does ibogaine work? Understanding matrix logic to make a safer drugColumbia University professor Dalibor Sames has proposed a theory called "matrix pharmacology" to explain how the hallucinogen ibogaine works, suggesting it impacts multiple molecules simultaneously rather than binding to a single target. DemeRx recently received FDA approval for the first-ever U.S. trial of an ibogaine-derived drug, while Gilgamesh Pharmaceuticals recently executed a major deal with AbbVie to develop safer ibogaine analogs. The narrow window between ibogaine's therapeutic effects and adverse cardiac events—linked to more than two dozen deaths—makes drug development challenging, but understanding this mechanism could enable companies to create safer versions of the compound for treating serious mental health conditions.Insurance Business AmericaPsychedelic medicine and insurance: Scientific and strategic allegiance for the insurance industryA neuropsychopharmacologist argues that the insurance sector must proactively engage with the emerging psychedelic medicine field, which has seen two positive Phase III readouts from Lykos Therapeutics (MDMA for PTSD) and Compass Pathways (psilocybin for treatment-resistant depression), alongside major pharmaceutical investments including AbbVie's $1.2 billion deal for Gilgamesh Pharmaceuticals and Otsuka Pharmaceutical's $1.225 billion acquisition of Transcend Therapeutics. The article projects the global psychedelic therapeutics market to exceed $8 billion by 2030 and outlines clinical, regulatory, and reputational risks insurers must address as the sector moves toward mainstream adoption.pharmaphorumTrump signs order to hasten psychedelic medicine accessPresident Trump signed an executive order directing the FDA to reduce regulatory hurdles for psychedelic medicines for serious mental illness. The order extends the Commissioner's National Priority Voucher for breakthrough therapy-designated psychedelics and allocates $50 million for research and clinical trials. It also calls for a pathway under the Right to Try Act for eligible patients.InvestorsWill Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?Health Secretary Robert F. Kennedy Jr., an outspoken advocate for psychedelic drugs as mental health treatments, is expected to push these substances into the mainstream, potentially creating a multibillion-dollar biopharma market projected to reach $9 billion this decade. Major pharmaceutical companies are positioning themselves in this space, with AbbVie recently spending $1.2 billion to acquire Gilgamesh Pharmaceuticals, while Compass Pathways awaits a potential FDA approval for its psilocybin-based treatment for treatment-resistant depression. Significant obstacles remain, including DEA classification that says psychedelic drugs have no medical use, the challenge of maintaining study blinding due to the obvious psychedelic experience, and stigma surrounding these substances.Stock TitanEnveric posts Q4 loss, advances EB-003 toward INDEnveric Biosciences reported a Q4 2025 net loss of $4.0 million with a basic and diluted loss per share of $6.12, compared to a net loss of $3.2 million in Q4 2024, while advancing its lead neuroplastogen candidate EB-003 toward an IND submission to the FDA following positive preclinical results in depression and PTSD models. The company raised $12.2 million in gross proceeds during fiscal year 2025 through warrant inducements and at-the-market offerings, and completed a reverse stock split in October 2025. Enveric successfully defended its intellectual property portfolio when AbbVie withdrew a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals pertaining to patents relevant to the bretisilocin molecule acquired in a $1.2 billion deal.citybizGilgamesh Pharma Closes $60 Million Series AGilgamesh Pharma, a clinical-stage neuroscience company developing therapies for psychiatric and neurological disorders, announced the closing of a $60 million Series A financing round led by Satori Neuro with participation from Prime Movers Lab and other institutional investors. The funding will support advancement of the company's pipeline including blixeprodil, its NMDA receptor antagonist for major depressive disorder that showed positive Phase 2 results, as well as its ibogaine analog GM-3009 entering Phase 1 studies. Gilgamesh Pharma was formed as a spinout following AbbVie's 2025 acquisition of Gilgamesh Pharmaceuticals, inheriting programs not acquired and maintaining an ongoing collaboration with AbbVie on neuroplastogen therapeutics.Venture Capital Access OnlineGilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric TherapiesGilgamesh Pharma announced the successful closing of a $60 million Series A financing round, the company's first formal capital raise since spinning out from AbbVie's 2025 acquisition of Gilgamesh Pharmaceuticals. The funding will advance the company's neuropsychiatric pipeline, including blixeprodil (GM-1020) which demonstrated clinically meaningful and statistically significant improvements in major depressive disorder in Phase 2 trials and is advancing to late-stage studies. The round was led by Satori Neuro with participation from Prime Movers Lab and other institutional investors, and will also support a cardio-safe ibogaine analog (GM-3009) entering Phase 1 studies later this year.SecSEC FORM DGilgamesh Pharma Inc., a Delaware-incorporated pharmaceutical company headquartered in New York, filed a Form D notice with the SEC on March 24, 2026, to notify regulators of an exempt offering of securities under Rule 506(b). The company raised $60 million from 40 investors through the sale of preferred stock and convertible capital stock, with a minimum outside investment of $50,000. The filing indicates the offering was completed with no remaining amount to be sold and no sales commissions or finder's fees paid.